Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy A Yap

Showing results (231-240 of 261) with videos related to

Pageof 27
Sort By:
Molecular Cancer Research : MCR|December 16, 2020
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient OutcomesOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Cancer Discovery|April 19, 2026
A Roadmap to Transform Lung Cancer Outcomes: Priorities in Biology, Therapeutic Innovation, Early Detection, Prevention and InterceptionMonte M Winslow, Mohamed A Ahmed, Christine D Berg, et al.
JAMA Oncology|November 17, 2022
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic TrialAlison M Schram, Nicoletta Colombo, Edward Arrowsmith, et al.
Nature|July 17, 2020
The National Lung Matrix Trial of personalized therapy in lung cancerGary Middleton, Peter Fletcher, Sanjay Popat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2022
A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 ResistanceTimothy A Yap, Patricia M LoRusso, Deborah J Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2026
The pan-tumor landscape of gene amplifications and copy number amplification ratio for established and emerging clinical targetsJessica K Lee, Julia C F Quintanilha, Kuei-Ting Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2020
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid TumorsTimothy A Yap, Brent O'Carrigan, Marina S Penney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2014
Antitumor activity in RAS-driven tumors by blocking AKT and MEKAnthony W Tolcher, Khurum Khan, Michael Ong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b ResultsEzra Y Rosen, Timothy A Yap, Elisa Fontana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2023
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)Funda Meric-Bernstam, James M Ford, Peter J O'Dwyer, et al.
Pageof 27

Showing results (231-240 of 261) with videos related to

Sort By:
Pageof 27
Molecular Cancer Research : MCR|December 16, 2020
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient OutcomesOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Cancer Discovery|April 19, 2026
A Roadmap to Transform Lung Cancer Outcomes: Priorities in Biology, Therapeutic Innovation, Early Detection, Prevention and InterceptionMonte M Winslow, Mohamed A Ahmed, Christine D Berg, et al.
JAMA Oncology|November 17, 2022
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic TrialAlison M Schram, Nicoletta Colombo, Edward Arrowsmith, et al.
Nature|July 17, 2020
The National Lung Matrix Trial of personalized therapy in lung cancerGary Middleton, Peter Fletcher, Sanjay Popat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2022
A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 ResistanceTimothy A Yap, Patricia M LoRusso, Deborah J Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2026
The pan-tumor landscape of gene amplifications and copy number amplification ratio for established and emerging clinical targetsJessica K Lee, Julia C F Quintanilha, Kuei-Ting Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2020
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid TumorsTimothy A Yap, Brent O'Carrigan, Marina S Penney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2014
Antitumor activity in RAS-driven tumors by blocking AKT and MEKAnthony W Tolcher, Khurum Khan, Michael Ong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b ResultsEzra Y Rosen, Timothy A Yap, Elisa Fontana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2023
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)Funda Meric-Bernstam, James M Ford, Peter J O'Dwyer, et al.
Pageof 27